InsiderTrades.com logo
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story
Christopher Ellis net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Christopher Ellis Biography and Net Worth

COO of Vaccitech
Chris Ellis obtained both his Registered General Nurse and Registered Mental Nurse qualifications before spending several years working within the National Health Service.

Chris left the NHS for clinical research in 1992 and now has over 24 years’ experience in drug development. Chris has worked across all phases of research and has spent time working for Clinical Research Organisations, Site Management Organisations and Biotechnology companies during this time. Chris joined Vaccitech as Clinical Operations Head in August 2016 having previously been Project Lead with responsibility for the lead oncolytic virus programme in a biotechnology company in Oxfordshire.

What is Christopher Ellis' net worth?

The estimated net worth of Christopher Ellis is at least $203.25 as of August 24th, 2022. Mr. Ellis owns 75 shares of Vaccitech stock worth more than $203 as of April 19th. This net worth evaluation does not reflect any other investments that Mr. Ellis may own. Learn More about Christopher Ellis' net worth.

How do I contact Christopher Ellis?

The corporate mailing address for Mr. Ellis and other Vaccitech executives is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. Vaccitech can also be reached via phone at 44-18-6581-8808 and via email at [email protected].. Learn More on Christopher Ellis' contact information.

Has Christopher Ellis been buying or selling shares of Vaccitech?

Christopher Ellis has not been actively trading shares of Vaccitech over the course of the past ninety days. Most recently, Christopher Ellis sold 450 shares of the business's stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $4.78, for a transaction totalling $2,151.00. Following the completion of the sale, the chief operating officer now directly owns 75 shares of the company's stock, valued at $358.50. Learn More on Christopher Ellis' trading history.

Who are Vaccitech's active insiders?

Vaccitech's insider roster includes Karen Dawes (Director), Christopher Ellis (COO), Graham Griffiths (Insider), and Robin Wright (Director). Learn More on Vaccitech's active insiders.

Are insiders buying or selling shares of Vaccitech?

During the last year, Vaccitech insiders bought shares 2 times. They purchased a total of 23,750 shares worth more than $60,975.00. The most recent insider tranaction occured on June, 26th when Director Joseph Scheeren bought 10,000 shares worth more than $24,400.00. Insiders at Vaccitech own 6.0% of the company. Learn More about insider trades at Vaccitech.

Information on this page was last updated on 6/26/2023.

Christopher Ellis Insider Trading History at Vaccitech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2022Sell450$4.78$2,151.0075View SEC Filing Icon  
8/18/2022Sell2,175$4.84$10,527.0075View SEC Filing Icon  
6/28/2022Sell5$6.00$30.0075View SEC Filing Icon  
5/4/2021Buy75$17.00$1,275.0075View SEC Filing Icon  
See Full Table

Christopher Ellis Buying and Selling Activity at Vaccitech

This chart shows Christopher Ellis's buying and selling at Vaccitech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaccitech Company Overview

Vaccitech logo
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $2.71
Low: $2.53
High: $2.77

50 Day Range

MA: $2.75
Low: $2.33
High: $5.00

2 Week Range

Now: $2.71
Low: $1.64
High: $5.10

Volume

7,707 shs

Average Volume

244,643 shs

Market Capitalization

$104.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story